SION Key Statistics, Chart & Performance
The current stock price of SION is 39.25 USD. In the past month the price decreased by -4.76%.
SION Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About SION
Company Profile
Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2025-02-07. The firm is focused on researching and developing novel medicines for cystic fibrosis. The company is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). The company is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. The company is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Company Info
SIONNA THERAPEUTICS INC
21 Hickory Drive, Suite 500
Waltham MASSACHUSETTS US
Employees: 41
Phone: 16178192020
SIONNA THERAPEUTICS INC / SION FAQ
What does SION do?
Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2025-02-07. The firm is focused on researching and developing novel medicines for cystic fibrosis. The company is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). The company is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. The company is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
What is the current price of SION stock?
The current stock price of SION is 39.25 USD. The price increased by 7.24% in the last trading session.
What is the dividend status of SIONNA THERAPEUTICS INC?
SION does not pay a dividend.
How is the ChartMill rating for SIONNA THERAPEUTICS INC?
SION has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is SIONNA THERAPEUTICS INC (SION) stock traded?
SION stock is listed on the Nasdaq exchange.
Can you provide the ownership details for SION stock?
You can find the ownership structure of SIONNA THERAPEUTICS INC (SION) on the Ownership tab.
SION Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to SION.
SION Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SION. SION has a great financial health rating, but its profitability evaluates not so good.
SION Financial Highlights
Over the last trailing twelve months SION reported a non-GAAP Earnings per Share(EPS) of -4.87. The EPS decreased by -30.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.83% | ||
| ROE | -21.97% | ||
| Debt/Equity | 0 |
SION Forecast & Estimates
14 analysts have analysed SION and the average price target is 43.42 USD. This implies a price increase of 10.63% is expected in the next year compared to the current price of 39.25.